- Enveric Biosciences (NASDAQ: ENVB) announced data from a preclinical rodent model evaluating EV102, the corporate’s cannabidiol (CBD) based mostly product in improvement for the topical therapy of radiodermatitis.
- Radiodermatitis, the most typical facet impact of radiation remedy, is a bodily pores and skin irritation with signs starting from purple rash to open wounds. It impacts almost 95% of sufferers who obtain radiation for most cancers therapy.
- EV102 was topically utilized throughout a each day therapy routine and resulted in an almost 50% discount in redness scoring severity.
- Comparable outcomes have been obtained for general dermatitis severity, together with desquamation (pores and skin peeling) and ulceration as a part of a composite rating.
- The corporate plans to begin Part 1 research in 2H of 2022.
- Associated Hyperlink: You Ask, We Analyze: Enveric Biosciences Stock Looks Ready To Skyrocket.
- Value Motion: ENVB shares are down 2.61% at $1.66 through the market session on the final test Thursday.
© 2021 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
